Fundraising Fox
Cellens
Boston, US · Founded 2020 · Delaware corporation · 4 known investors
Find your way into Cellens
Sign up to see every warm intro you have to Cellens
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cellens team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Cellens develops a non-invasive, urine-based cancer diagnostics platform (Octosense) that uses nanoscale atomic-force imaging of single-cell biophysical markers combined with machine learning to detect cancer, with early data focused on bladder cancer detection. It applies mechanobiology and label-free cell analysis to cancer screening.
Founders & leadership
Cellens was founded in 2020 by Phuong (Jean) Pham.
Board
Investors · 4
How we know: Cancer Fund's portfolio page · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · sosv.com · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$7M disclosed across 2 rounds · 2022–2025
▶$6.4MraisedNov 2025 · 33 investors · Other Health CareRule 506(b)
- Deborah ZajacDirector
- Lena Chaihorsky-HeringDirector
- Mohan IyerDirector
- Jesse SalkDirector
- Phuong (Jean) PhamExecutive Officer, Director
- Offering amount
- $6.4M
- Amount sold
- $6.4M
- Minimum investment
- $747
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$585KraisedOct 2022 · 15 investors · OtherRule 506(b)
- Phuong Nhu PhamExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $585K
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Cellens.
Frequently asked questions
- What does Cellens do?
- Cellens develops a non-invasive, urine-based cancer diagnostics platform (Octosense) that uses nanoscale atomic-force imaging of single-cell biophysical markers combined with machine learning to detect cancer, with early data focused on bladder cancer detection. It applies mechanobiology and label-free cell analysis to cancer screening.
- Who founded Cellens?
- Cellens was founded by Phuong (Jean) Pham in 2020.
- Who are Cellens's investors?
- Cellens's investors include Cancer Fund, Creative Destruction Lab (CDL), SOSV, IndieBio.
- How much funding has Cellens raised?
- Cellens has disclosed $7M raised across 2 rounds.
- Where is Cellens headquartered?
- Cellens is headquartered in Boston, US.